145 related articles for article (PubMed ID: 23136718)
1. Preparation and characterization of gemcitabine liposome injections.
Zhou Q; Liu L; Zhang D; Fan X
Pharmazie; 2012 Oct; 67(10):844-7. PubMed ID: 23136718
[TBL] [Abstract][Full Text] [Related]
2. Analysis of gemcitabine liposome injection by HPLC with evaporative light scattering detection.
Zhou Q; Liu L; Zhang D; Fan X
J Liposome Res; 2012 Dec; 22(4):263-9. PubMed ID: 22428966
[TBL] [Abstract][Full Text] [Related]
3. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
4. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.
Calvagno MG; Celia C; Paolino D; Cosco D; Iannone M; Castelli F; Doldo P; Frest M
Curr Drug Deliv; 2007 Jan; 4(1):89-101. PubMed ID: 17269921
[TBL] [Abstract][Full Text] [Related]
5. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Deodhar S; Dash AK; North EJ; Hulce M
AAPS PharmSciTech; 2020 Aug; 21(6):231. PubMed ID: 32778980
[TBL] [Abstract][Full Text] [Related]
6. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Bersani S; Vila-Caballer M; Brazzale C; Barattin M; Salmaso S
Eur J Pharm Biopharm; 2014 Nov; 88(3):670-82. PubMed ID: 25157908
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific delivery of gemcitabine with activatable liposomes.
Tucci ST; Kheirolomoom A; Ingham ES; Mahakian LM; Tam SM; Foiret J; Hubbard NE; Borowsky AD; Baikoghli M; Cheng RH; Ferrara KW
J Control Release; 2019 Sep; 309():277-288. PubMed ID: 31301340
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
9. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
Tang M; Svirskis D; Leung E; Kanamala M; Wang H; Wu Z
J Control Release; 2019 Jul; 305():89-100. PubMed ID: 31096017
[TBL] [Abstract][Full Text] [Related]
10. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z
Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells.
Celano M; Calvagno MG; Bulotta S; Paolino D; Arturi F; Rotiroti D; Filetti S; Fresta M; Russo D
BMC Cancer; 2004 Sep; 4():63. PubMed ID: 15363094
[TBL] [Abstract][Full Text] [Related]
12. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
Cosco D; Bulotta A; Ventura M; Celia C; Calimeri T; Perri G; Paolino D; Costa N; Neri P; Tagliaferri P; Tassone P; Fresta M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1009-20. PubMed ID: 19263052
[TBL] [Abstract][Full Text] [Related]
13. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
15. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
Bornmann C; Graeser R; Esser N; Ziroli V; Jantscheff P; Keck T; Unger C; Hopt UT; Adam U; Schaechtele C; Massing U; von Dobschuetz E
Cancer Chemother Pharmacol; 2008 Mar; 61(3):395-405. PubMed ID: 17554540
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-coated liposomes for active targeting of gemcitabine.
Arpicco S; Lerda C; Dalla Pozza E; Costanzo C; Tsapis N; Stella B; Donadelli M; Dando I; Fattal E; Cattel L; Palmieri M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):373-80. PubMed ID: 23791684
[TBL] [Abstract][Full Text] [Related]
17. PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation.
Kanamala M; Palmer BD; Ghandehari H; Wilson WR; Wu Z
Pharm Res; 2018 May; 35(8):154. PubMed ID: 29855807
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Immordino ML; Brusa P; Rocco F; Arpicco S; Ceruti M; Cattel L
J Control Release; 2004 Dec; 100(3):331-46. PubMed ID: 15567500
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H
Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816
[TBL] [Abstract][Full Text] [Related]
20. Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug.
Xu H; Paxton JW; Wu Z
Pharm Res; 2015 Jul; 32(7):2428-38. PubMed ID: 25663325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]